Clinica Baviera (CBAV) AI Stock Analysis

• Market Cap: €709.20M
• Dividend Yield: 3.09%
• Average Volume (3M): 8.30K
• Price to Earnings (P/E): 17.3
• Beta (1Y): 0.39
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: ES
• Employees: 1,706
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 16,307,580
• 10 Day Avg. Volume: 6,694
• 30 Day Avg. Volume: 8,303
• PEG Ratio: 10.80
• Price to Book (P/B): 6.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 16.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 78 Outperform
• Price Target: €50.00 ▲(14.94%Upside)

Clinica Baviera's strong financial performance is the primary driver of the stock score, supported by robust revenue growth, profitability, and a debt-free balance sheet. The technical analysis indicates strong momentum, although caution is advised due to overbought technical indicators. The valuation is fair with a reasonable P/E ratio and an attractive dividend yield, further supporting the company's stock appeal.

Clinica Baviera Business Overview & Revenue Model

Company Description

Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, cornea, neuroftalmología, vías lagrimales, and oculoplasty treatments. It operates approximately 90 centers in Spain, Germany, Austria, and Italy. The company is based in Madrid, Spain.

How the Company Makes Money

Clínica Baviera generates revenue primarily through the provision of medical services related to ophthalmology. The company's key revenue streams include fees for surgical procedures such as laser eye surgeries, cataract operations, and other specialized treatments for eye conditions. Additionally, Clínica Baviera may earn income from consultations, diagnostic services, and follow-up care. The company benefits from strategic partnerships with medical technology providers and maintains a strong brand presence in the healthcare sector, which contributes to its ability to attract patients and sustain its earnings.

Clinica Baviera Financial Statement Overview

Summary

Clinica Baviera exhibits strong financial health, driven by consistent revenue and profit growth, a robust balance sheet with no debt, and efficient cash flow management. The company's financial statements reflect a well-managed enterprise with strong profitability and stable operations. While cash flow growth is moderate, the overall financial position is solid, providing a strong foundation for future growth.

Income Statement

Clinica Baviera has demonstrated strong and consistent revenue growth over the past years, with a Revenue Growth Rate of 16.74% from 2023 to 2024. The Gross Profit Margin for 2024 is robust at 88.37%, reflecting efficient cost management. The company also maintains healthy profitability with a Net Profit Margin of 15.31% and an EBIT Margin of 21.20%, indicating strong operational efficiency. However, there is room for improvement in EBITDA Margin, which stands at 29.73%.

Balance Sheet

The company's balance sheet is solid, with a Debt-to-Equity Ratio of 0.00 in 2024, showcasing no reliance on debt financing. The Equity Ratio is strong at 45.72%, indicating a well-capitalized structure. Return on Equity is impressive at 41.49%, reflecting effective use of shareholders' equity to generate profit. The balance sheet stability is a significant strength for Clinica Baviera.

Cash Flow

Clinica Baviera has shown consistent Free Cash Flow generation, with a Free Cash Flow to Net Income Ratio of 0.90 in 2024, indicating efficient conversion of net income into cash. The Operating Cash Flow to Net Income Ratio is healthy at 1.56, suggesting strong cash generation from operations. However, the Free Cash Flow Growth Rate is modest at 3.19%, indicating limited growth in cash flows compared to previous years.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	277.81M	262.65M	224.92M	198.45M	172.73M	122.63M
Gross Profit	189.12M	232.08M	197.85M	172.95M	151.25M	107.37M
EBITDA	80.78M	78.11M	67.22M	56.15M	53.49M	34.06M
Net Income	40.66M	40.20M	35.97M	29.52M	27.39M	13.94M
Balance Sheet
Total Assets	230.34M	211.95M	178.64M	150.10M	133.81M	120.92M
Cash, Cash Equivalents and Short-Term Investments	53.44M	38.58M	51.24M	38.99M	32.27M	26.94M
Total Debt	61.13M	63.47M	47.41M	39.98M	51.56M	54.84M
Total Liabilities	118.94M	113.59M	86.37M	81.74M	78.42M	76.02M
Stockholders Equity	110.27M	96.92M	91.00M	67.34M	54.60M	44.49M
Cash Flow
Free Cash Flow	41.87M	36.25M	35.13M	39.35M	36.28M	23.64M
Operating Cash Flow	66.74M	62.76M	57.81M	53.38M	46.86M	31.46M
Investing Cash Flow	-31.30M	-20.90M	-44.31M	-12.56M	-17.08M	-21.40M
Financing Cash Flow	-40.51M	-39.91M	-24.37M	-31.45M	-30.80M	-3.15M

Clinica Baviera Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 43.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:CBAV, the sentiment is Positive. The current price of 43.5 is above the 20-day moving average (MA) of 41.19, above the 50-day MA of 39.42, and above the 200-day MA of 34.85, indicating a bullish trend. The MACD of 1.37 indicates Negative momentum. The RSI at 65.35 is Neutral, neither overbought nor oversold. The STOCH value of 83.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:CBAV.

Clinica Baviera Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CBAV	78 Outperform	€709.20M	17.31		3.09%	―	―
Sector *	64 Neutral	¥343.53B	10.93	-2.99%	2.55%	11.77%	-9.96%
0K9H	―	€1.42B	12.73	16.04%	6.07%	―	―
0RB1	―	€245.01M	22.19	5.11%	1.40%	―	―
0R9G	―	€109.71M	11.25	31.66%	17.70%	―	―
5P1	―	€194.91M	15.50		3.83%	―	―
A2T	―	€220.34M	―	-11.64%	―	―	―

Clinica Baviera Corporate Events

Clínica Baviera Shareholders Approve Key Proposals at General Meeting

The Ordinary General Meeting of Shareholders of Clínica Baviera, S.A. approved all proposals by the Board of Directors, with 86.36% of the share capital represented. Key decisions included the approval of the annual accounts, management report, non-financial information statement, and sustainability report for 2024, as well as the re-election of Forvis Mazars Auditores as auditor for 2025. These approvals reflect strong shareholder support and are expected to positively impact the company’s governance and operational transparency.

Clínica Baviera Appoints New Vice Presidents to Board

Clínica Baviera has announced the appointment of Ms. Yongmei Zhang and Mr. Eduardo Baviera Sabater as vice presidents of its Board of Directors. This strategic leadership change is expected to enhance the governance structure of the company, potentially impacting its strategic direction and stakeholder engagement.

Clinica Baviera Proposes New Director Remuneration Policy for 2025-2028

Clinica Baviera, S.A. has announced its remuneration policy for directors, which will be proposed for approval at the next General Shareholders’ Meeting for the period 2025-2028. The policy, which maintains the structure of the previous one, emphasizes a balance between fixed and variable remuneration components to align with the company’s long-term objectives and reduce exposure to excessive risks.

Clínica Baviera Announces Ordinary General Meeting of Shareholders

Clínica Baviera’s Board of Directors has announced the convening of its Ordinary General Meeting of Shareholders on May 27, 2025, with a second call on May 28, 2025, if necessary. The meeting will address several key agenda items, including the approval of annual accounts, management reports, and directors’ remuneration, as well as the re-election of auditors. This meeting is crucial for stakeholders as it will determine the company’s financial and strategic direction for the upcoming year.

Clinica Baviera Announces 2024 Dividend Details

Clinica Baviera has announced the details of its upcoming dividend distribution for the 2024 financial year, with a fixed unit amount of 1.57 euros gross per share. The Ordinary General Meeting has been convened to finalize the payment, which will be facilitated by CaixaBank and processed through IBERCLEAR, with relevant dates set for June 2025.